Showing 3751-3760 of 4764 results for "".
- Depression, Psoriasis And Risk Of Psoriatic Arthritis: What's the Connection?https://practicaldermatology.com/news/depression-psoriasis-and-risk-of-psoriatic-arthritis-whats-the-connection/2458269/Psoriasis patients who develop depression are at a 37 percent greater risk of developing psoriatic arthritis, compared with psoriasis patients who did not develop depression, according to a new
- DermMentors™ 2017 Resident of Distinction Award Honors Five Dermatology Residentshttps://practicaldermatology.com/news/dermmentors-2017-resident-of-distinction-award-honors-five-dermatology-residents/2458273/As part of the dermMentors™ Resident of Distinction Award program, sponsored by Beiersdorf Inc., five dermatology residents attended the 16th Annual Caribbean Dermatology Symposium in Aruba, Netherlands Antilles, from January 17 - 21, 2017
- FDA Approves Valeant's SILIQ For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-valeants-siliq-for-moderate-to-severe-plaque-psoriasis/2458283/The FDA has approved the Biologics License Application (BLA) for Valeant Pharmaceutical's SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis. SILIQ is indicated for the treatment of mo
- Rumor Has It Syneron Is Next In Week of Surprising Aquisitionshttps://practicaldermatology.com/news/rumor-has-it-syneron-is-next-in-week-of-surprising-aquisitions/2458286/Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners is looking to buy Syneron Medical for $350-$400 million. According to Israeli finan
- Medical Spa State of the Industry Statistical Study Now Openhttps://practicaldermatology.com/news/medical-spa-state-of-the-industry-statistical-study-now-open/2458301/During the past five years, the medical spa industry has grown and evolved to a point where it has become one of the most exciting and lucrative new industries in the country. Because of this, it is now more important than ever that the industry have its own credible state of the industry report.
- Teamwork: Solésence and Colorescience Announce Skin Care Collaborationhttps://practicaldermatology.com/news/teamwork-solsence-and-colorescience-announce-skin-care-collaboration/2458303/Solésence is teaming up with Colorescience to develop products for skin care and protection. Solésence will use patented mineral skin care actives technology to develop sunscreen products exc
- Realm Therapeutics Submits Investigational New Drug Application for PR022 for Atopic Dermatitishttps://practicaldermatology.com/news/realm-therapeutics-submits-investigational-new-drug-application-for-pr022-for-atopic-dermatitis/2458305/Realm Therapeutics plc submitted its first investigational new drug (IND) application to the FDA for PR022 as a novel treatment for atopic dermatitis (AD). Pending acceptance, the IND will enable Realm to initiate a Phase 2a proof-of-concept trial for patients with atopic dermatitis.
- New from Coppertone®: Whipped Sunscreenhttps://practicaldermatology.com/news/new-from-coppertone-whipped-sunscreen/2458309/COPPERTONE® is rolling out new Whipped formula sunscreens. The new formulas are available in the CLEARLYSheer® and WaterBABIES® Pure & Simple line. “For my patients, one of the biggest barriers to using everyday su
- Radiesse Hits Double Digitshttps://practicaldermatology.com/news/radiesse-hits-double-digits/2458312/Merz Aesthetics’ flagship brand, Radiesse, turned 10 this year, and was feted in style at a throw-back Thursday media event in New York City. The party took beauty bloggers and journos back to 2007 when the first iPhone was released to the publi
- ISDIN: Broad Spectrum Sun Protection Cream with DNA Repair Beneficial Post AK Treatmenthttps://practicaldermatology.com/news/isdin-broad-spectrum-sun-protection-cream-with-dna-repair-beneficial-post-ak-treatment/2458319/ISDIN has reported promising results of a 9-month, randomized, investigator-blinded parallel-group study in a poster presentation at the Winter Clinical Conference. The study was designed to evaluate clinical effects of a high SPF film-forming emulsion co